Mark A. Cierpial, Ph.D, RAC
Vice President of Regulatory Affairs and Strategic Drug Development Services
Mark A. Cierpial is responsible for the provision of international regulatory
affairs, medical writing, and drug development services. Cierpial’s biomedical
research experience covers a broad range of therapeutic areas, and includes
work on both drugs and biologics.
Cierpial joined Constella through its acquisition of Lineberry Research Associates
(LRA) in 2006. At LRA, Cierpial was the Chief Operating Officer, overseeing
all aspects of the CROs clinical, regulatory, biometrics, and quality assurance
operations. Earlier in his career, Cierpial spent five years on the research
faculty in the Department of Psychiatry at the Duke University Medical Center.
He then started his pharmaceutical industry career by joining the Clinical
Neurosciences Department at Burroughs Wellcome Co. At Burroughs Wellcome Co.,
and then GlaxoWellcome, Cierpial worked on clinical development programs for
drugs in epilepsy and smoking cessation, and was the International Product
Development Team Leader for a novel antipsychotic agent.
Cierpial holds a B.A. in Biology and in Psychology from the George Washington
University, and a Ph.D. in Behavioral Neuroscience from the University of Virginia.
He also earned his U.S. Regulatory Affairs Certification (RAC) from the Regulatory
Affairs Professional Society (RAPS).
|
